Canada Clears Seegene Diarrhea Test

Jan 11, 2010

NEW YORK (GenomeWeb News) – Seegene said today that its PCR-based test for detecting viral diarrhea has been cleared for use in Canada by a government health regulator.

The company’s Seeplex Diarrhea-V ACE Detection test received a Medical Device License from Health Canada.

The company, based in Rockville, Md., and Seoul, Korea, said that the test has already been permitted for use in more than 30 countries recognizing the CE Mark.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Scan

Marks Left on the Genome

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

Cost and Coverage of Gene Therapies

The Wall Street Journal looks into the cost of new gene therapies.

Mosquito Population Crash

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

This Week in PNAS

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

Featured White Papers

Discovering Neuronal Cell Types

Highly Resolved Separation of DNA Fragments on the Fragment Analyzer

FEMTO Pulse Genomic DNA Sizing and Quality Control

xMAP Cookbook: A collection of methods and protocols for developing multiplex assays with xMAP Technology

Oct

02

Featured Webinar

Utilization of Multiple Molecular Testing Methodologies to Aid in Lung Cancer Patient Management

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.

Oct

10

Featured Webinar

Personalization of Oncology Pathways: Clinical Quality Initiatives Amid a Complex Molecular Landscape

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Nov

07

Featured Webinar

Implementation of a Comprehensive NGS Oncology Panel including MSI and TMB Signatures

This webinar will provide a first-hand look at how a leading pathology lab implemented a next-generation sequencing panel to capture comprehensive molecular tumor profiles.

Main menu